Vol. 1 No. 11 (2021)
Reimbursement Recommendations

Trientine Hydrochloride (MAR-Trientine)

Published November 29, 2021

Key Messages

  • CADTH recommends that MAR-Trientine should be reimbursed by public drug plans for the treatment of patients with Wilson's disease if certain conditions are met.
  • MAR-Trientine should only be covered to treat patients who have previously tried and demonstrated intolerance to d-penicillamine.
  • MAR-Trientine should only be reimbursed if initiated by clinicians experienced in the management of Wilson’s disease and if the cost of MAR-Trientine is reduced.